Loading…
Humacyte, Inc. is projected to decline to $0.6708 by 2027, a -3% move from its current price of $0.6937. HUMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.6472 | $0.6934 | $0.7429 | -0.05% |
| Jul 14 | $0.6287 | $0.6931 | $0.7641 | -0.09% |
| Jul 15 | $0.6147 | $0.6928 | $0.7807 | -0.14% |
| Jul 16 | $0.6032 | $0.6924 | $0.7949 | -0.18% |
| Jul 17 | $0.5932 | $0.6921 | $0.8075 | -0.23% |
| Jul 18 | $0.5843 | $0.6918 | $0.8192 | -0.27% |
| Jul 19 | $0.5762 | $0.6915 | $0.8299 | -0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5762 | $0.6915 | $0.8299 | -0.32% |
| Week 2 | $0.5325 | $0.6893 | $0.8923 | -0.63% |
| Week 3 | $0.5009 | $0.6871 | $0.9425 | -0.95% |
| Week 4 | $0.4755 | $0.6849 | $0.9866 | -1.26% |
| Week 5 | $0.454 | $0.6828 | $1.03 | -1.58% |
| Week 6 | $0.4353 | $0.6806 | $1.06 | -1.89% |
| Week 7 | $0.4186 | $0.6784 | $1.10 | -2.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Humacyte, Inc. is a healthcare company focused on developing and manufacturing off-the-shelf, implantable, and bioengineered human tissues. It uses a proprietary technology platform to engineer human acellular vessels (HAVs) that can be implanted without inducing a foreign body response or immune rejection.
The HAVs are aimed at vascular repair, reconstruction, and replacement across multiple therapeutic areas, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation. Humacyte was founded in 2004 and is headquartered in Durham, North Carolina. The company is categorized under Healthcare.
Humacyte, Inc. (HUMA) trades at $0.7003 per share, and its market capitalization is $188.83M. The stock ranks 3868 by market cap. The 30-day technical picture shows bearish momentum with RSI at 40, and the price trading below key moving averages: SMA50 is $0.9931 and SMA200 is $1.14.
Support is at $0.62 and resistance at $1.49, with the 30-day price range spanning $0.4381 to $1.12. Looking ahead, the 2026 forecast shows an average price of $0.7003 with neutral sentiment and 0% ROI; longer-term projections rise toward 2030, 2040, and 2050, including 2030 avg $0.7199 (ROI 2.8%, Neutral), 2040 avg $0.9432 (ROI 34.7%, Bullish), and 2050 avg $2.16 (ROI 208.3%, Bullish).
A major floor 90.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 114.8% above — a clean break opens room to run.
A major ceiling 160.2% above — clearing it would confirm fresh momentum.
Key HUMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HUMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7338 | Sell | $0.718 | Sell |
| MA 10 | $0.734 | Sell | $0.7465 | Sell |
| MA 20 | $0.8162 | Sell | $0.8257 | Sell |
| MA 50 | $0.99 | Sell | $0.9173 | Sell |
| MA 100 | $0.9432 | Sell | $0.9828 | Sell |
| MA 200 | $1.13 | Sell | $1.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.13 | Neutral |
| Stoch RSI (14) | 72.79 | Neutral |
| CCI (20) | -65.03 | Neutral |
| Williams %R (14) | -66.21 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -0.86 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 33.79 | Neutral |
| TRIX (15) | -1.38 | Sell |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 34.65 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.72 | Sell |
| ADX (14) | 23.68 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bearish, with the RSI14 at 40 indicating modest downside momentum. The price remains below the SMA50 ($0.9931) and the SMA200 ($1.14), suggesting continued near-term pressure beneath these averages. Support sits at $0.62 and resistance at $1.49, while the 30-day range extends from $0.4381 up to $1.12.
The stock exhibits substantial annualized volatility at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.575 | $0.6937 | $0.8913 | 0% | Neutral | |
| $0.4867 | $0.6708 | $0.9996 | -3% | Neutral | |
| $0.3726 | $0.5457 | $0.8666 | -21% | Bearish | |
| $0.3335 | $0.5146 | $0.8578 | -26% | Bearish | |
| $0.4351 | $0.7037 | $1.22 | +1% | Neutral | |
| $0.4756 | $0.804 | $1.44 | +16% | Neutral | |
| $0.4853 | $0.8557 | $1.59 | +23% | Bullish | |
| $0.4323 | $0.7939 | $1.51 | +14% | Neutral | |
| $0.344 | $0.6572 | $1.28 | -5% | Neutral | |
| $0.3971 | $0.7885 | $1.57 | +14% | Neutral | |
| $0.4148 | $0.9217 | $2.02 | +33% | Bullish | |
| $0.9433 | $2.10 | $4.82 | +202% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.575 | $0.6937 | $0.8122 | +0.00% |
| August 2026 | $0.5488 | $0.6646 | $0.8384 | -4.19% |
| September 2026 | $0.5418 | $0.6655 | $0.8572 | +0.14% |
| October 2026 | $0.5022 | $0.6244 | $0.8183 | -6.18% |
| November 2026 | $0.4915 | $0.6176 | $0.8211 | -1.10% |
| December 2026 | $0.5215 | $0.6616 | $0.8913 | +7.13% |
Click any year to see its month-by-month HUMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HUMA price prediction for 2026 points to an average of $0.6937 (low $0.575, high $0.8913) — a potential gain of 0% on today's $0.6937. Price action looks broadly range-bound.
In 2027, HUMA is projected to trade between $0.4867 and $0.9996, averaging $0.6708 — a potential decline of -3% from today's $0.6937. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Humacyte, Inc.'s 2028 outlook centres on $0.5457, within a $0.3726 to $0.8666 range. That is -19% versus the projected 2027 average. That marks a -21% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2029, HUMA could reach as high as $0.8578, with a base case around $0.5146 and support toward $0.3335 — roughly -26% from $0.6937. Expect choppier, lower action through this leg of the cycle.
Expect HUMA to range from $0.4351 to $1.22 through 2030. The $0.7037 average target implies a +1% move from current prices. That is up +37% on the projected 2029 average. Price action looks broadly range-bound.
The HUMA price prediction for 2031 points to an average of $0.804 (low $0.4756, high $1.44) — a potential gain of +16% on today's $0.6937. A consolidation phase looks the most probable path here.
In 2032, HUMA is projected to trade between $0.4853 and $1.59, averaging $0.8557 — a potential gain of +23% from today's $0.6937. That is up +6% on the projected 2031 average. Momentum favours further upside here.
Humacyte, Inc.'s 2033 outlook centres on $0.7939, within a $0.4323 to $1.51 range. That is -7% versus the projected 2032 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, HUMA could reach as high as $1.28, with a base case around $0.6572 and support toward $0.344 — roughly -5% from $0.6937. Price action looks broadly range-bound.
Expect HUMA to range from $0.3971 to $1.57 through 2035. The $0.7885 average target implies a +14% move from current prices. That is up +20% on the projected 2034 average. A consolidation phase looks the most probable path here.
The HUMA price prediction for 2040 points to an average of $0.9217 (low $0.4148, high $2.02) — a potential gain of +33% on today's $0.6937. Momentum favours further upside here.
In 2050, HUMA is projected to trade between $0.9433 and $4.82, averaging $2.10 — a potential gain of +202% from today's $0.6937. That is up +127% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HUMA today (≈ 1,441.545337 HUMA) could be worth
$3,021.67
+$2,021.67 (+202%) by 2050 · US Dollar
Based on the average projected HUMA price of $2.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HUMAwould be worth at today's price.
$1,000 invested in HUMA on Jul 10, 2025 (≈ 398.406376 HUMA) would be worth
$276.37
-$723.63 (-72.4%) today · 0.28× · US Dollar
Based on a HUMA entry price of $2.51 vs. today's $0.6937.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.71 | $977.04 | -2.3% |
| 1 month ago | $1.34 | $517.69 | -48.2% |
| 3 months ago | $0.645 | $1,075.5 | +7.6% |
| 6 months ago | $1.13 | $613.89 | -38.6% |
| 1 year ago | $2.51 | $276.37 | -72.4% |
| All time (5.0y) ago | $10.24 | $67.74 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HUMA forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $377.49M
In the near term, the forecast shows a neutral stance for 2026 with an average price of $0.7003 and a 0% ROI. Beyond 2026, the outlook becomes more mixed through 2029, with 2027 at an average of $0.6744 (ROI -3.7%, Neutral) and 2028 at $0.5531 (ROI -21%, Bearish) and 2029 at $0.5250 (ROI -25%, Bearish). By 2030 the average price rises to $0.7199 with a small positive ROI of 2.8% and Neutral sentiment, followed by 2031 at $0.8232 (ROI 17.6%, Neutral) and 2032 at $0.8715 (ROI 24.4%, Bullish).
The longer-term horizon shows stronger upside, with 2040 averaging $0.9432 (ROI 34.7%, Bullish) and 2050 averaging $2.16 (ROI 208.3%, Bullish). These projections suggest meaningful optionality if the underlying business advances, but they also incorporate periods of volatility and downside risk in earlier years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.7199 with a 2.8% ROI and Neutral sentiment.
Forecasts show neutral sentiment in 2026 with an average of $0.7003 and 0% ROI, then Neutral in 2030 with 2.8% ROI, followed by Bullish signals in 2040 (34.7% ROI) and 2050 (208.3% ROI). These are estimates, not guarantees, and depend on many factors.
Yes, the forecast includes years with maximum prices above $1, such as 2027 max $1.01 and 2032 max $1.61, as well as higher peaks in later years (2040 max $2.07 and 2050 max $4.97). The average prices by those years are $0.6744 (2027), $0.8715 (2032), $0.9432 (2040), and $2.16 (2050).
The 2040 forecast lists an average price of $0.9432 with a max of $2.07 and a ROI of 34.7% with Bullish sentiment.
The 2050 forecast lists an average price of $2.16 with a max of $4.97 and a ROI of 208.3% with Bullish sentiment.
Humacyte, Inc. Community Discussion
0Share your Humacyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.